[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

Evelyn E. C. de Jong*, Wouter van Elmpt, Ralph T. H. Leijenaar, Otto S. Hoekstra, Harry J. M. Groen, Egbert F. Smit, Ronald Boellaard, Vincent van der Noort, Esther G. C. Troost, Philippe Lambin, Anne-Marie C. Dingemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)8-16
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume44
Issue number1
DOIs
Publication statusPublished - Jan 2017

Keywords

  • [18F]FDG PET/CT
  • Response assessment
  • Nitroglycerin
  • Bevacizumab
  • Stage IV NSCLC
  • POSITRON-EMISSION-TOMOGRAPHY
  • RANDOMIZED PHASE-II
  • TUMOR RESPONSE
  • F-18-FDG PET
  • HYPOXIA
  • CHEMOTHERAPY
  • QUANTIFICATION
  • CHEMOSENSITIVITY
  • ERLOTINIB
  • SURVIVAL

Cite this